304456-62-0
Chemical Structure
BTYNB
- CAS No.: 304456-62-0
- Formula:C12H9BrN2OS
- Molecular Weight:309.18
IUPAC Name: (E)-2-(((5-bromothiophen-2-yl)methylene)amino)benzamide
InChIKey: OZEADOPONHLEDS-VIZOYTHASA-N
SMILES: O=C(C1=CC=CC=C1/N=C/C2=CC=C(S2)Br)N
Biological Activity: BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC50 of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BTYNB | 98.0% | BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC50 of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bley N, et al. Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer. Signal Transduct Target Ther. 2025;10(1):419. Published 2025 Dec 25. [Content Brief]
- [2]. Wang J J, et al. Elevated Expression of The RNA-Binding Protein IGF2BP1 Enhances The Mrna Stability and Translation E ciency of INHBA to Promote The Invasion and Migration of Esophageal Squamous Cancer Cells[J]. 2022.
- [3]. Hagemann S, et al. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression[J]. Molecular cancer, 2023, 22(1): 88.
- [4]. Jamal A, et al. BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells. Saudi J Biol Sci. 2023;30(3):103569. [Content Brief]
- [5]. Mahapatra L, et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol. 2017;10(5):818-827. [Content Brief]
Keywords
